Navigation Links
Drug Self-Administration to 2018 - Drug Products, Indications, Markets and Forecasts
Date:6/5/2013

DUBLIN, June 5, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/bvckj3/drug) has announced the addition of the "Drug Self-Administration to 2018 Drug Products, Indications, Markets and Forecasts" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered orally. Because they cannot tolerate the first-pass metabolism of the digestive tract, the recent escalation in new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies.

Now a number of factors are converging to create both risk and opportunity for drug makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs. These factors are giving rise to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the formulation limitations of new classes of therapeutic drugs. Because of their ability to safely and reliably satisfy treatment protocols and compliance goals, non-oral drug delivery products will have a significant impact on the future of drug self-administration.

Highlights

- Provides detailed analysis of drug self-administration market segments, market dynamics and market demographics

- Analyzes therapeutic demand drivers and evaluates commercial drug products in more than two dozen major self-administration therapeutic segments

- Analyzes design factors, material selection issues, technologies and market development issues for injection devices, inhalation devices and transdermal drug products designed for self-administration

- Charts product data, market share, and forecasts to 2018

-Profiles self-administration drug product and device participants, their product development activities, business strategies, and corporate alliances and affiliations

For more information visit http://www.researchandmarkets.com/research/bvckj3/drug

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716


Sector: Drug Delivery


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
2. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
3. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
4. Advanced Devices for Injectable Drugs: Products, Players and Prospects - 2013 Report
5. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
6. Oral Transmucosal Drug Delivery. Products, Players, Markets & Forecasts
7. Global Biosimilars Market - Products, Applications and Regulations
8. New Avenues to Market - Research Report on Isis Pharmaceuticals, Inc., Avon Products, Inc., Elizabeth Arden, Inc., Boyd Gaming Corporation and Ameristar Casinos, Inc.
9. Cardiology Point of Care Diagnostics: Products, players & outlook to 2017
10. Wright Therapy Products, Inc. Closes $3 million Financing Round
11. China Biologic Products, Inc. Adopts Stockholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Phoenix Marketing Solutions ( Phoenix ) ... mission of transforming science into clinical practice. During a time ... innovative approach supports the life sciences industry by ... in science and medicine — which ultimately improves lives. ... 2002 by Tracy Doyle and Angela Fiordilino ...
(Date:4/20/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... and Gynecology markets with innovative and proprietary products, ... Company as Senior Vice President, Marketing & Business ... will report directly to Darin Hammers , ... delighted that Ash has joined the Cogentix team," ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Somnoware, a leading provider of digital ... enables sleep physicians to create and edit their interpretation reports. This solution greatly ... familiar interface that does not require additional training to use. It also allows ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it also ... hours without sleep can compromise motor reaction time, which can increase the risk of having ... sharing the following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
Breaking Medicine News(10 mins):